Affitope PD03

Drug Profile

Affitope PD03

Alternative Names: Affitope-PD03; Affitope-PD03A; PD03; PD03A

Latest Information Update: 07 Nov 2016

Price : $50

At a glance

  • Originator AFFiRiS
  • Class Antiparkinsonians; Peptide vaccines
  • Mechanism of Action Alpha-synuclein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple system atrophy; Parkinson's disease

Most Recent Events

  • 01 Aug 2016 AFFiRiS completes a phase I trial for Parkinson's disease (Early-stage disease) in Austria (NCT02267434)
  • 04 Apr 2016 Phase-I development is ongoing in Austria and France
  • 01 Nov 2014 Phase-I clinical trials in Multiple system atrophy (Early-stage disease) in France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top